Dan hong Wang, Guoliang Ding, Liangding Hu, Min Jiang, Bin Zhang, Hongmei Ning, Yuhang Li, Chen Xu, Xiao Lou, Jinchao Zhang, Hu Chen

Department of Hematopoietic Stem Cell Transplantation, Affiliated Hospital of Academy of Military Medical Sciences

Objective:Acute myeloid leukemia (AML) relapse after allogeneic hematopoietic cell transplantation (allo-HSCT) remainsa major therapeutic challenge. DC vaccination andadoptive CIK cell transfer, provided proof-of-principle in trials with respectto therapeutic immunity being elicited leading to clinical responses. We conducted a retrospective analysis to evaluate Clinical efficacy and safety of Patients With relapsed Acute myeloid leukaemia after Allogeneic hematopoietic cell transplantation treated With Dendritic cells and cytokine-induced killer cell. Method: we conducted a retrospective analysis to evaluate Clinical efficacy and safety of 23 Patients With relapsed Acute myeloid leukaemia after Allogeneic hematopoietic cell transplantation treated With Dendritic cells and cytokine-induced killer cell between2009 and 2014. Result: Overall CR rate was 73.9% (17of 23), of which CR rate of haematological relapse andmolecular relapse is 60% (6/10) and 84.6% (11/13), respectively. There is no significant difference between haematological relapse patients and molecular relapse patients (P=0.183).Overall GVHD rate was 52.2% (12 of 23), of which GVHD rate of haematological relapse and molecular relapse is 50% (5 of 10) and 53.8% (7 of 13), respectively. No Serious graft-versus-host disease wasobserved in any patient. Conclusion: These results indicate that dendritic cellscombined with cytokine-induced killer cells (DC-CIK) mayprovide a promising treatment method for Patients With relapsed Acute myeloidleukaemia after Allogeneic hematopoietic cell transplantation.

Key Words: Acute myeloid leukaemia  Allogeneic hematopoietic